Readoutin 103d
Ionis Pharmaceuticals, Inc. — Olezarsen
Phase 3 primary completion: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG).
- Date
- Mar 2027
- Type
- Readout
- Indication
- Severe Hypertriglyceridemia